Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma

Stephen Maxted Ansell, Anne J Novak, Steven Ziesmer, Tammy Price-Troska, Betsy Laplant, Stacey R. Dillon, Thomas Elmer Witzig

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Serum B-lymphocyte stimulator (BLyS) levels are elevated in a subset of non-Hodgkin lymphoma (NHL) patients, particularly those with a family history of B-cell malignancies or a polymorphism in the BLyS gene. BLyS promotes growth of malignant B-cells and increased serum BLyS levels are associated with a poor clinical outcome. In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL. A significant increase was seen in the serum levels of BLyS (P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene. Am. J. Hematol.

Original languageEnglish (US)
Pages (from-to)71-73
Number of pages3
JournalAmerican Journal of Hematology
Volume84
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

B-Cell Activating Factor
Non-Hodgkin's Lymphoma
Serum
Therapeutics
B-Lymphocytes
Rituximab
Genes
Growth

ASJC Scopus subject areas

  • Hematology

Cite this

Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma. / Ansell, Stephen Maxted; Novak, Anne J; Ziesmer, Steven; Price-Troska, Tammy; Laplant, Betsy; Dillon, Stacey R.; Witzig, Thomas Elmer.

In: American Journal of Hematology, Vol. 84, No. 2, 02.2009, p. 71-73.

Research output: Contribution to journalArticle

@article{e3b5272c1d3040178c4d03a9fb2177dd,
title = "Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma",
abstract = "Serum B-lymphocyte stimulator (BLyS) levels are elevated in a subset of non-Hodgkin lymphoma (NHL) patients, particularly those with a family history of B-cell malignancies or a polymorphism in the BLyS gene. BLyS promotes growth of malignant B-cells and increased serum BLyS levels are associated with a poor clinical outcome. In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL. A significant increase was seen in the serum levels of BLyS (P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene. Am. J. Hematol.",
author = "Ansell, {Stephen Maxted} and Novak, {Anne J} and Steven Ziesmer and Tammy Price-Troska and Betsy Laplant and Dillon, {Stacey R.} and Witzig, {Thomas Elmer}",
year = "2009",
month = "2",
doi = "10.1002/ajh.21328",
language = "English (US)",
volume = "84",
pages = "71--73",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma

AU - Ansell, Stephen Maxted

AU - Novak, Anne J

AU - Ziesmer, Steven

AU - Price-Troska, Tammy

AU - Laplant, Betsy

AU - Dillon, Stacey R.

AU - Witzig, Thomas Elmer

PY - 2009/2

Y1 - 2009/2

N2 - Serum B-lymphocyte stimulator (BLyS) levels are elevated in a subset of non-Hodgkin lymphoma (NHL) patients, particularly those with a family history of B-cell malignancies or a polymorphism in the BLyS gene. BLyS promotes growth of malignant B-cells and increased serum BLyS levels are associated with a poor clinical outcome. In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL. A significant increase was seen in the serum levels of BLyS (P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene. Am. J. Hematol.

AB - Serum B-lymphocyte stimulator (BLyS) levels are elevated in a subset of non-Hodgkin lymphoma (NHL) patients, particularly those with a family history of B-cell malignancies or a polymorphism in the BLyS gene. BLyS promotes growth of malignant B-cells and increased serum BLyS levels are associated with a poor clinical outcome. In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL. A significant increase was seen in the serum levels of BLyS (P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene. Am. J. Hematol.

UR - http://www.scopus.com/inward/record.url?scp=59949089567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59949089567&partnerID=8YFLogxK

U2 - 10.1002/ajh.21328

DO - 10.1002/ajh.21328

M3 - Article

C2 - 19051265

AN - SCOPUS:59949089567

VL - 84

SP - 71

EP - 73

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -